A solid body of evidence validates prediction of chemotherapy benefit
It is the only genomic test to fulfill the criteria for level 1 evidence for prognosis and prediction of chemotherapy benefit in patients with early-stage, hormone receptor—positive invasive breast cancer.4,6-8
Clinical validation studies
In total, 4 validation studies—involving nearly 3000 patients—have been performed. The studies show that the Oncotype DX Breast Recurrence Score® test is:4,6-8
Strongly associated with the rate of distant recurrence
A low score indicating a significantly lower rate of distant recurrence and a lower likelihood of chemotherapy benefit6,7
Predictive for likelihood of benefit from chemotherapy
A high score indicating a higher rate of distant recurrence and predicting a significant benefit from chemotherapy4,8
| Node-Negative | Node-positive |
|---|---|
| TAILORx Trial1-4 | RxPONDER Trial5,9-11 |
|
10,273 patients
Recurrence Score result <25 Identified 70% of women with no chemotherapy benefit who would have been overtreated View the landmark trial details View additional node-negative data |
5083 patients
Recurrence Score result <25 Postmenopausal women (1-3 +nodes) can forgo chemotherapy Premenopausal women (1-3 +nodes) modestly benefit from chemotherapy View trial details View additional node-positive data |
TAILORx + RxPONDER results elevate the Oncotype DX Breast Recurrence Score test to the next level of precision with the highest quality of evidence.
GIVING YOU
Clear, meaningful results for more impactful conversations with patients about the magnitude of chemotherapy benefit.
STANDARD OF CARE
With prospective outcomes in over 100,000 patients – including over 12,000 node-positive patients2,5,9,11-14
PROVEN
To be predictive of chemotherapy benefit in both node-positive and node negative patients4,8
CLINICALLY VALIDATED
In multiple studies with consistent results (Level 1 evidence for risk of distant recurrence and prediction of chemotherapy benefit)4,8
Proven to help patients with a low Recurrence Score result avoid chemotherapy
Several separate studies, with a total of more than 63,000 patients, found that patients with a low Recurrence Score result may be effectively treated with hormonal therapy alone and safely spared chemotherapy.1,13,15-20-
References
Use our online physician portal
Order tests, access results, receive updates, and more in one place.
Sign up now